Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine

2014 ◽  
Vol 20 (14) ◽  
pp. 2275-2292 ◽  
Author(s):  
Mohamed Altai ◽  
Anna Orlova ◽  
Vladimir Tolmachev
2021 ◽  
Vol 22 (13) ◽  
pp. 6978
Author(s):  
Maria J. Iraburu ◽  
Tommy Garner ◽  
Cristina Montiel-Duarte

The endocytosis of ligand-bound receptors and their eventual recycling to the plasma membrane (PM) are processes that have an influence on signalling activity and therefore on many cell functions, including migration and proliferation. Like other tyrosine kinase receptors (TKR), the insulin receptor (INSR) has been shown to be endocytosed by clathrin-dependent and -independent mechanisms. Once at the early endosome (EE), the sorting of the receptor, either to the late endosome (LE) for degradation or back to the PM through slow or fast recycling pathways, will determine the intensity and duration of insulin effects. Both the endocytic and the endosomic pathways are regulated by many proteins, the Arf and Rab families of small GTPases being some of the most relevant. Here, we argue for a specific role for the slow recycling route, whilst we review the main molecular mechanisms involved in INSR endocytosis, sorting and recycling, as well as their possible role in cell functions.


2014 ◽  
Vol 10 (3) ◽  
pp. 355-363 ◽  
Author(s):  
Jianhong Li ◽  
Cynthia L. Jackson ◽  
Dongfang Yang ◽  
Lelia Noble ◽  
Michael Wheeler ◽  
...  

2015 ◽  
Vol 172 (1) ◽  
pp. K1-K3 ◽  
Author(s):  
Louis de Mestier ◽  
Thomas Walter ◽  
Hedia Brixi ◽  
Catherine Lombard-Bohas ◽  
Guillaume Cadiot

VIPomas are rare-functioning neuroendocrine tumors (NETs). Overproduction of vasointestinal peptide (VIP) leads to the Verner–Morrison syndrome, whose management is challenging when refractory to somatostatin analogs. Two patients with progressive metastatic pancreatic NETs and refractory VIPoma symptoms were treated with sunitinib. This led to fast and sustained total relief of VIPoma symptoms, enabling earlier discharge from hospital and improvement in their quality of life. In both cases, sunitinib discontinuation led to the quick recurrence of watery diarrhea, which resolved within a few days after reintroducing sunitinib. The anti-secretory effect of sunitinib on VIPoma syndrome was probably not related to any anti-tumor effect. These observations agree with the rare reported cases of anti-secretory effects with targeted therapies. The sunitinib-driven inhibition of multiple-tyrosine kinase receptors might act on secretory pathways and describe sunitinib's ability to improve VIPoma symptoms. Sunitinib could be a therapeutic option to control refractory VIPoma symptoms in patients with NETs.


2013 ◽  
Vol 37 (9) ◽  
pp. 1394-1403 ◽  
Author(s):  
Stefano Sartini ◽  
Fanny Bartolini ◽  
Patrizia Ambrogini ◽  
Michele Betti ◽  
Stefano Ciuffoli ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document